News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

Nomination Committee for the 2016 Annual General Meeting in PledPharma AB

November 11, 2015

PledPharma AB
Company Announcement

Nomination Committee for the 2016 Annual General Meeting in PledPharma AB

Stockholm, 2015-11-11 08:30 CET (GLOBE NEWSWIRE) -- 

The Chairman of PledPharma AB has established a Nomination Committee for the
Annual General Meeting that is to be held on April 14, 2016. The Nomination
Committee consists of Staffan Persson, Peter Lindell and Astrid Samuelsson. The
members of the Nomination Committee have been appointed by PledPharma’s three
largest shareholders. The Nomination Committee has elected Staffan Persson as
Chairman of the Committee. Håkan Åström (Chairman of PledPharma) has been
co-opted to the Nomination Committee. 

The Committee's task is to present to the Annual General Meeting proposals
regarding Chairman and other members of the board as well as fees and other
remuneration to the Board´s members. The Nomination Committee shall also submit
proposals for appointment and remuneration of auditors. Further, the Committee
shall submit proposals to the process to appoint the Nomination Committee for
the AGM in 2017. 

Shareholders who wish to submit proposals to the Nomination Committee can do so
by email: 

For more information please contact:

Håkan Åström, Chairman, phone: +46 703 747 213

Jacques Näsström, CEO, phone: +46 737 130 979

About PledPharma

PledPharma develops new drugs that protect the body against oxidative stress –
a condition that can be caused by chemotherapy treatment and acetaminophen
(paracetamol) poisoning. The company's most advanced project PledOx® reduces
the nerve damage associated with chemotherapy. The drug candidate Aladote® is
being developed to reduce the risk of acute liver failure associated with
acetaminophen poisoning. The project PP-099 seeks to limit the damage that
occurs to the heart muscle during myocardial infarction. PledPharma’s most
advanced project with PledOx® has completed Phase II trial. PledPharma (STO:
PLED) is listed on Nasdaq First North. Erik Penser Bankaktiebolag is the
company’s Certified Adviser (tel +46 8 463 80 00). For more information, see



Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10